Oxular

Oxular is a UK-based startup focused on building a global ophthalmic franchise to address the unmet need for treatments for retinal diseases. Their sustained-release formulations are designed to last up to one year following a single administration, offering a potential paradigm shift in the treatment of retinal diseases. By delivering precise drug distribution to the specific tissues involved in such conditions, Oxular aims to enhance therapeutic effectiveness, patient safety, and quality of life, while minimizing side effects and the frequency of treatments.

The company, founded in 2014, is targeting prevalent retinal diseases like diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers. In March 2021, Oxular secured a significant $37.00M Series B investment from prominent investors including Forbion, IP Group, NeoMed Management, and V-Bio Ventures. This funding is expected to propel Oxular's innovative drug administration technology and product development pipeline forward, potentially positioning the company as a disruptive force in the treatment of retinal diseases.